CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
What to Expect From These Drug/Biotech Players This Earnings Season?
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
